Global Branded Generics Market: Key Developments
In April 2020, Dr. Reddy\'s Laboratories Ltd. introduced Invista in India. This product is the branded generic version of Sprycel (dasatinib) indicated for the treatment of adult patients with Chronic Myeloid Leukemia (CML).
Moreover, In January 2020, Endo International plc. announced that one of its operating companies, Par Pharmaceutical, has begun shipping an authorized generic version of Allergan\'s Carafate (sucralfate) oral suspension 1gm/10 mL to the U.S.
Global Branded Generics Market: Key Trends
Rising prevalence of chronic diseases and increasing penetration of branded generic drugs is driving the growth of market
Increase in prevalence of chronic diseases is like drive the growth of market. For instance a per Centers for Disease Control data in September 2020, around 25.5% of US adults had multiple diagnosed chronic conditions among 10 different conditions: arthritis, cancer, chronic obstructive pulmonary disease (COPD), coronary heart disease, current asthma, diabetes, hepatitis, hypertension, stroke, and weak or failing kidneys. Compared with adults without chronic conditions, adults with multiple chronic conditions have worse health-related quality of life, higher health care costs, and increased risk of death. Thus, owing to the above factors, the demand for cheap and effective branded generics is rising, which is driving the market growth rapidly.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients